We are a pharmaceutical company dedicated to advancing the clinical development and commercialization of innovative immunotherapy solutions for infectious diseases, with a particular focus on viral encephalitis. Viral encephalitis, a severe and often fatal inflammation of the brain caused by viral infections, remains a critical unmet medical need. Among the most devastating examples is rabies encephalitis, caused by the rabies virus, which is nearly 100% fatal once symptoms appear and the virus reaches the brain. Despite advances in medical science, there are currently no effective treatments for rabies encephalitis.
Our lead program targets rabies encephalitis with our novel compound, IMT504, which has received Orphan Drug Designation (ODD) in the United States for its potential to treat this rare and deadly condition. This designation underscores the urgent need for therapeutic interventions and positions us to pursue pivotal clinical trials. A successful trial could lead to rapid FDA approval, qualification for a Priority Review Voucher (PRV), and significant near-term revenue opportunities, as PRVs have recently been sold for $150 million.
In addition to rabies, other viruses such as herpes simplex virus (HSV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and enteroviruses also contribute to cases of viral encephalitis worldwide. These infections can cause severe neurological complications and pose significant public health challenges. For example, herpes simplex brain infections occur throughout the world, are the most common cause of viral encephalitis and incur very large health expenditures in the developed world with considerable rates of morbidity and mortality. Our broader mission is to create transformative therapies that address these critical threats, redefining treatment paradigms for viral diseases and improving patient outcomes globally.